NUCYNTA (tapentadol hydrochloride) by Humanwell Pharmaceutical is centrally-acting synthetic analgesic. First approved in 2008.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
NUCYNTA (tapentadol HCl) is a centrally-acting synthetic opioid analgesic approved in 2008 that works through dual mechanisms: mu-opioid receptor agonism and norepinephrine reuptake inhibition. It is indicated for moderate to severe pain management via oral tablet formulation. The dual mechanism differentiates it from traditional opioids by engaging both opioid and noradrenergic pathways.
Product is in late-stage exclusivity with minimal linked job openings, signaling a small or consolidating brand team focused on transition planning rather than growth initiatives.
centrally-acting synthetic analgesic. The exact mechanism of action is unknown. Although the clinical relevance is unclear, preclinical studies have shown that tapentadol is a mu-opioid receptor (MOR) agonist and a norepinephrine reuptake inhibitor (NRI). Analgesia in animal models is derived from…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain
A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain
Worked on NUCYNTA at Humanwell Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Working on NUCYNTA offers limited career growth given imminent LOE and minimal current job openings. Career prospects are best suited for professionals seeking experience in managed decline, portfolio transition, or last-mile commercial optimization rather than innovation or expansion.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo